9989 — Shenzhen Hepalink Pharmaceutical Share Price
Last trade - 00:00- HK$5.89bn
- HK$4.49bn
- CNY5.48bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.88 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -6.96% | ||
| Dividend Yield (f) | 1.72% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.42 | ||
| Price to Tang. Book | 0.52 | ||
| Price to Free Cashflow | 3 | ||
| Price to Sales | 0.99 | ||
| EV to EBITDA | 9.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.41% | ||
| Return on Equity | 1.55% | ||
| Operating Margin | 3.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 6,365.18 | 7,159.41 | 5,445.57 | 5,280.71 | 5,478.98 | 4,958.95 | 5,188.32 | 0.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -61.93 | +82.49 | n/a | n/a | -10.69 | +6.49 | -8.82 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The Company operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The Company conducts its business in the domestic and overseas markets.
Directors
- Li Li CHM (62)
- Yu Shan GMG (66)
- Tan Li DGM (62)
- Fengqi Qian SEC (41)
- Juan Chen CFO (51)
- Peng Huang IND (77)
- Ming Yi IND (49)
- Hong Pu IND (61)
- Jianyi Wang DRC (44)
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- April 21st, 1998
- Public Since
- May 6th, 2010
- No. of Shareholders
- 25,396
- No. of Employees
- 2,150
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,467,296,204
- Address
- No. 21, Langshan Road,, SHENZHEN, 518057
- Web
- https://www.hepalink.com/
- Phone
- +86 75526980311
- Auditors
- Ernst & Young Hua Ming
Latest News for 9989
Similar to 9989
160 Health International
Stock Exchange of Hong Kong Limited
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ab&B Bio-Tech JS
Stock Exchange of Hong Kong Limited
AIM Vaccine
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 11:06 UTC, shares in Shenzhen Hepalink Pharmaceutical are trading at HK$4.02. This share price information is delayed by 15 minutes.
Shares in Shenzhen Hepalink Pharmaceutical last closed at HK$4.02 and the price had moved by -29.93% over the past 365 days. In terms of relative price strength the Shenzhen Hepalink Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -44.99% over the past year.
The overall consensus recommendation for Shenzhen Hepalink Pharmaceutical is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Shenzhen Hepalink Pharmaceutical dividend yield is 4.25% based on the trailing twelve month period.
Last year, Shenzhen Hepalink Pharmaceutical paid a total dividend of CNY0.15, and it currently has a trailing dividend yield of 4.25%. We do not have any data on when Shenzhen Hepalink Pharmaceutical is to next pay dividends.
We do not have data on when Shenzhen Hepalink Pharmaceutical is to next pay dividends. The historic dividend yield on Shenzhen Hepalink Pharmaceutical shares is currently 4.25%.
To buy shares in Shenzhen Hepalink Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$4.02, shares in Shenzhen Hepalink Pharmaceutical had a market capitalisation of HK$5.89bn.
Here are the trading details for Shenzhen Hepalink Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 9989
Based on an overall assessment of its quality, value and momentum Shenzhen Hepalink Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shenzhen Hepalink Pharmaceutical is HK$3.75. That is 6.56% below the last closing price of HK$4.02.
Analysts covering Shenzhen Hepalink Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of CNY0.34 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shenzhen Hepalink Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -7.45%.
As of the last closing price of HK$4.02, shares in Shenzhen Hepalink Pharmaceutical were trading -10.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shenzhen Hepalink Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 10.88. The shares last closed at HK$4.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shenzhen Hepalink Pharmaceutical's management team is headed by:
- Li Li - CHM
- Yu Shan - GMG
- Tan Li - DGM
- Fengqi Qian - SEC
- Juan Chen - CFO
- Peng Huang - IND
- Ming Yi - IND
- Hong Pu - IND
- Jianyi Wang - DRC